Clinical Trial Update: Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating oral deucrictibant for prophylaxis and acute treatment in hereditary angioedema patients; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioedema
• Bradykinin-mediated Angioedema
• C1 Esterase Inhibitor Deficiency
• Hereditary Angioedema

Drugs mentioned

• Deucrictibant (Deucrictibant)

Snippet

Sponsor: Institute for Asthma and Allergy | Conditions: Hereditary Angioedema (HAE), Angioedema | Phase 1, Phase 2 | Status: RECRUITING